^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
INDUCTION REGIMENS FOR Ph-POSITIVE ALL: Other Recommended regimens…TKI + vincristine + dexamethasone…TKI options include (in alphabetical order): bosutinib, dasatinib, imanitib, nilotinib or ponatinib.
Secondary therapy:
vincristine
Evidence Level:
Sensitive: C1 - Off-label
  (Approved for Chronic Myeloid Leukemia)
New
Excerpt:
Tasigna is indicated for the treatment of:...adult and paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase…
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

NILOTINIB PLUS CHEMOTHERAPY IN PEDIATRICS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LEUKEMIA: A SINGLE CENTER EXPERIENCE

Published date:
05/11/2023
Excerpt:
Our study evaluated the use of nilotinib in combination with chemotherapy in pediatrics with Ph-positive acute leukaemia. These promising results suggest nilotinib based therapy was safe and resulted in deep molecula rresponses in pediatric Ph-positive acute leukaemia with BCR-ABL1-positive and dasatinib intolerance...
Secondary therapy:
Chemotherapy
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Nilotinib (Tasigna®) and Low Intensity Chemotherapy for First-Line Treatment of Elderly Patients with BCR-ABL1-Positive Acute Lymphoblastic Leukemia: Final Results of a Prospective Multicenter Trial (EWALL-PH02)

Published date:
11/01/2018
Excerpt:
Nilotinib combined with low-intensity chemotherapy is well tolerated and highly effective in elderly pts. with Ph-positive ALL.
Secondary therapy:
vincristine
DOI:
https://doi.org/10.1182/blood-2018-99-114552
Evidence Level:
Sensitive: C3 – Early Trials
New
Source:
Title:

Nilotinib (Tasigna®) and Low Intensity Chemotherapy for First-Line Treatment of Elderly Patients with BCR-ABL1-Positive Acute Lymphoblastic Leukemia: Final Results of a Prospective Multicenter Trial (EWALL-PH02)

Excerpt:
...72/79 enrolled pts. were evaluable for response, 3 withdrew consent, 4 did not meet eligibility criteria...Sixty-eight of 72 pts. (94.4%) achieved CR, one died during induction and one was refractory, 2 pts discontinued study therapy...EFS and OS at 4 years was 42%, and 47%, respectively...The proportion of pts. with a BCR-ABL1/ABL1 ratio ≤0.1% increased from 41% after induction to 86% after consolidation 2; that of pts. with undetectable or non quantifiable BCR-ABL1 transcripts (sensitivity ≥10-4) increased from 14% to 58%....Nilotinib combined with low intensity chemotherapy is well tolerated and highly effective in elderly pts. with Ph-positive ALL. OS and EFS compare favorably with previous similar studies testing imatinib or dasatinib.
Secondary therapy:
vincristine
DOI:
https://doi.org/10.1182/blood-2018-99-114552